Type 2 diabetes mellitus and associated metabolic disorders, prevalence within the working-age population
https://doi.org/10.58708/2074-2088.2024-1(31)-118-123
Abstract
Over an 11-year observation period, type 2 diabetes mellitus (E11) was recorded in isolated cases at the age of 25-29 years against the preceding background of primary incidence of obesity associated with excess intake of energy resources (E66). A low incidence of various forms of impaired glucose tolerance was reported (R73). The incidence rate of dyslipidemia (E78) was comparable to the incidence rate of type 2 diabetes mellitus.
Predictors and risk of developing type 2 diabetes mellitus were determined in more than 1,5 thousand healthy respondents. More than 80,0% of respondents had a low 10-year risk of developing type 2 diabetes mellitus. However, the analysis indicated a negative effect of atherogenic lipids on the levels of hemoglobin glycation, a probable effect on the development of insulin resistance, an increased risk of prediabetes and clinical and laboratory manifestations of type 2 diabetes mellitus in patients with a high 10-year risk. In the group of healthy workingage respondents, the RR high risk/low risk (according to Findrisk) of prediabetes was 2,58 (1,58; 4,22) and was statistically significant.
Analysis of factors influencing the risk of developing type 2 diabetes mellitus showed a high prevalence of both modifiable and non-modifiable risk factors in all groups of the workingage population of the Republic of Belarus.
When planning activities for the primary prevention of non-communicable diseases in the population, it is necessary to be based on the results of the assessment and the feasibility of reducing population risks. Risk assessment makes it possible to identify and form followup groups of population for which it is possible to administer preventive treatment to correct metabolic disorders.
About the Authors
I. G. SavasteevaBelarus
Yu. I. Yarets
Belarus
K. V. Bronskaya
Belarus
Yu. S. Kandzera
Belarus
References
1. Cardiovascular disease in Europe– epidemiological update / N. Townsend [et al.] // Eur Heart J . – 2015. – V. 36. – P. 2696-2705.
2. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) // European Heart Journal. – 1 January 2020. – V. 41, Issue 1. – P. 111-188.
3. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate and hyperglycaemia. Report of a WHO/IDF consultation. Доступно по: http://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/ (June 14 2019).
4. American Diabetes Association ADA. Standards of medical care in diabetes-2020. Diabetes Care 2020.
5. 2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD // European Heart Journal. – 2019. – V.00. P.1-69 ESC GUIDELINES.
6. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care // Obes Facts. – 2019. – V.12. – P.40-66. Published online: January 23, 2019.
Review
For citations:
Savasteeva I.G., Yarets Yu.I., Bronskaya K.V., Kandzera Yu.S. Type 2 diabetes mellitus and associated metabolic disorders, prevalence within the working-age population. Medical and Biological Problems of Life Activity. 2024;(1):118-123. (In Russ.) https://doi.org/10.58708/2074-2088.2024-1(31)-118-123